A
70.13
0.11 (0.16%)
| 前收盘价格 | 70.02 |
| 收盘价格 | 71.27 |
| 成交量 | 668,356 |
| 平均成交量 (3个月) | 1,248,501 |
| 市值 | 5,338,491,904 |
| 股市价格/股市净资产 (P/B) | 8.74 |
| 52周波幅 | |
| 利润日期 | 11 Aug 2025 |
| 营业利益率 (TTM) | -4,865.98% |
| 稀释每股收益 (EPS TTM) | -3.45 |
| 季度收入增长率 (YOY) | -17.40% |
| 总债务/股东权益 (D/E MRQ) | 269.12% |
| 流动比率 (MRQ) | 1.25 |
| 营业现金流 (OCF TTM) | -152.60 M |
| 杠杆自由现金流 (LFCF TTM) | -87.22 M |
| 资产报酬率 (ROA TTM) | -48.60% |
| 股东权益报酬率 (ROE TTM) | -196.12% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | Abivax SA | 看涨 | 看涨 |
AIStockmoo 评分
1.3
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | -3.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 1.25 |
|
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 机构持股比例 | 50.19% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Great Point Partners I Lp | 31 Mar 2025 | 1,638,111 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 112.00 (Piper Sandler, 59.70%) | 购买 |
| 中 | 101.00 (44.02%) | |
| 低 | 95.00 (JMP Securities, 35.46%) | 购买 |
| 平均值 | 102.25 (45.80%) | |
| 总计 | 4 购买 | |
| 平均价格@调整类型 | 68.90 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Piper Sandler | 29 Jul 2025 | 112.00 (59.70%) | 购买 | 69.80 |
| 23 Jul 2025 | 70.00 (-0.19%) | 购买 | 68.60 | |
| Guggenheim | 23 Jul 2025 | 101.00 (44.02%) | 购买 | 68.60 |
| JMP Securities | 23 Jul 2025 | 95.00 (35.46%) | 购买 | 68.60 |
| LifeSci Capital | 23 Jul 2025 | 101.00 (44.02%) | 购买 | 68.60 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合